US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

FibroBiologics

1.38

+0.190015.97%

Post-market: 1.37-0.0088-0.64%18:14 EDT

Volume:499.57K

Turnover:659.82K

Market Cap:52.07M

PE:-4.06

High:1.44

Open:1.22

Low:1.15

Close:1.19

Loading ...

Overview Company News Filings

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR

Zacks Small Cap Research

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics announces opening of new lab facility

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

FibroBiologics Reports 2024 Financial Results and Updates

FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25…

Zacks Small Cap Research

BRIEF-Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair

Fibrobiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

THOMSON REUTERS

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

FibroBiologics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Press Release: FibroBiologics Announces 2025 Annual Meeting of Stockholders

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Uncovering Opportunities: 3 Penny Stocks With Market Caps Under $80M

Simply Wall St.

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

FibroBiologics Is Maintained at Buy by D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FBLG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":1.38,"timestamp":1745265600000,"preClose":1.19,"halted":0,"volume":499574,"hourTrading":{"tag":"盘后","latestPrice":1.3712,"preClose":1.38,"latestTime":"18:14 EDT","volume":8846,"amount":12083.713844799999,"timestamp":1745273696990},"delay":0,"floatShares":27939955,"shares":37735300,"eps":-0.339497,"marketStatus":"Post-Mkt","change":0.19,"latestTime":"04-21 18:26:42 EDT","open":1.22,"high":1.44,"low":1.15,"amount":659817.5061122001,"amplitude":0.243697,"askPrice":1.42,"askSize":327,"bidPrice":1.36,"bidSize":708,"shortable":3,"etf":0,"ttmEps":-0.339497,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":4,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":1.19,"preHourTrading":{"tag":"盘前","latestPrice":1.27,"preClose":1.19,"latestTime":"08:37 EDT","volume":2120,"amount":2524.889896,"timestamp":1745239056649},"postHourTrading":{"tag":"盘后","latestPrice":1.3712,"preClose":1.38,"latestTime":"18:14 EDT","volume":8846,"amount":12083.713844799999,"timestamp":1745273696990},"volumeRatio":1.660553},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":27939955,"roa":"-60.75%","roe":"-559.73%","lyrEps":-0.339497,"volumeRatio":1.660553,"shares":37735300,"dividePrice":0,"high":1.44,"amplitude":0.243697,"preClose":1.19,"low":1.15,"week52Low":0.7626,"pbRate":"19.04","week52High":13.59,"institutionHeld":0,"latestPrice":1.38,"committee":0.368116,"eps":-0.339497,"divideRate":0,"volume":499574,"delay":0,"ttmEps":-0.339497,"open":1.22,"prevYearClose":2,"prevWeekClose":1.19,"prevMonthClose":0.9,"prevQuarterClose":0.9,"fiveDayClose":0.89,"twentyDayClose":1.11,"sixtyDayClose":1.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526766673","title":"FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean","url":"https://stock-news.laohu8.com/highlight/detail?id=2526766673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526766673?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"HOUSTON, April  11, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (\"FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/11/3060072/0/en/FibroBiologics-to-Present-at-The-Cell-Gene-Meeting-on-the-Mediterranean.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2526345198","title":"OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2526345198","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526345198?lang=en_us&edition=fundamental","pubTime":"2025-04-10 00:21","pubTimestamp":1744215660,"startTime":"0","endTime":"0","summary":"Hello and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our quarterly conference. Our next live presentation is from FibroBiologics. FibroBiologics is a cell therapy regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases. Please note that you may submit questions for the presenter in the box on the left of the slides. You also may view a company's availability for one-on-one meetings by clicking Book Meeting in the top toolbar. At this point, I'm very pleased to welcome Peter O'Heeron. He's the founder and chief executive officer. David Bautz is a senior analyst with Zacks Small Cap Research. FibroBiologics trades on NASDAQ under the symbol FBLG. Welcome, Pete and David.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-hosts-virtual-investor-162100771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","BK4566","FBLG","BK4118","BK4552","BK4585","DB"],"gpt_icon":0},{"id":"2526335082","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2526335082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526335082?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:34","pubTimestamp":1744198440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 07:34 ET (11:34 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2525920892","title":"FibroBiologics announces opening of new lab facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2525920892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525920892?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:48","pubTimestamp":1744116520,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) announced the opening of a new laboratory facility that will expand the company’s ability to pioneer additional candidates fo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-announces-opening-of-new-lab-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-announces-opening-of-new-lab-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2525894954","title":"FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2525894954","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525894954?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology. HOUSTON, April 08, 2025  -- FibroBiologics, Inc.   , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the opening of a new laboratory facility that will expand the company’s ability to pioneer additional candidates for chronic disease-focused indications leveraging its novel fibroblast-based technology.The new laboratory space will increase the company’s pace of discovery for potential therapeutics including multiple chronic disease indications and will enhance the development of treatment candidates for upcoming target indications. The company plans to hire additional researchers to help staff the facility and join FibroBiologics’ mission to combat chronic diseases u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrobiologics-unveils-expanded-houston-laboratory-123000347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","FBLG","LENZ"],"gpt_icon":0},{"id":"2524422608","title":"FibroBiologics Reports 2024 Financial Results and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2524422608","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524422608?lang=en_us&edition=fundamental","pubTime":"2025-04-04 11:56","pubTimestamp":1743739003,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. ( ($FBLG) ) has released its Q4 earnings. Here is a breakdown of the information FibroBiologics, Inc. presented to its investo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-reports-2024-financial-results-and-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-reports-2024-financial-results-and-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2524902992","title":"FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25…","url":"https://stock-news.laohu8.com/highlight/detail?id=2524902992","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524902992?lang=en_us&edition=fundamental","pubTime":"2025-04-03 23:31","pubTimestamp":1743694260,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc.  is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers , which we anticipate initiating in the second quarter of 2025 and completing before the end of 2025. Recent activities the company has accomplished to support the upcoming clinical trial include:. The company does not utilize single cell fibroblasts for treatment but instead a fibroblast spheroid, which is composed of approximately 3,000 fibroblasts and is administered to the top of the wound at which time the cells migrate from the surface of the wound and release various cytokines and growth factors to initiate the wound healing process. The use of spheroids is more practical from a therapeutic perspective as they have higher viability than single cells, they don’t require pre-culturing before administra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fblg-phase-1-2-trial-153100735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDMO","EAE","BK4139","FBLG","SEPA"],"gpt_icon":0},{"id":"2524287498","title":"BRIEF-Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair","url":"https://stock-news.laohu8.com/highlight/detail?id=2524287498","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524287498?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:33","pubTimestamp":1743597196,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue RepairApril 2 (Reuters) - Fibrobiologics Inc FBLG.O:FIBROBIOLOGICS ANNOUNCES SCIENTIFIC ADVANCEMENT IN CON","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2524498557","title":"Fibrobiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair","url":"https://stock-news.laohu8.com/highlight/detail?id=2524498557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524498557?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:30","pubTimestamp":1743597054,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2524249333","title":"FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair","url":"https://stock-news.laohu8.com/highlight/detail?id=2524249333","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524249333?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:30","pubTimestamp":1743597000,"startTime":"0","endTime":"0","summary":"HOUSTON, April  02, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (\"FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/02/3054243/0/en/FibroBiologics-Announces-Scientific-Advancement-in-Confirmation-Results-of-Brain-Tissue-Repair.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EAE","FBLG","BK4139"],"gpt_icon":0},{"id":"2524197199","title":"FibroBiologics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197199?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:41","pubTimestamp":1743507660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 07:41 ET (11:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2524192878","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2524192878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524192878?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:14","pubTimestamp":1743506040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 07:14 ET (11:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2524177906","title":"FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524177906","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524177906?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:25","pubTimestamp":1743452700,"startTime":"0","endTime":"0","summary":"Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing. Preparations for Phase 1/2 clinical trial in Australia utilizing CYWC628 to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025. Cash and cash equivalents of approximately $14.0 million at December 31, 2024. HOUSTON, March 31, 2025  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,today announced full year 2024 financial results and provided a corporate update.Entered into a Standby Equity Purchase Agreement  with YA II PN LTD. , an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrobiologics-reports-full-2024-financial-202500544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FBLG","SEPA","BK4139"],"gpt_icon":0},{"id":"2522514370","title":"Press Release: FibroBiologics Announces 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2522514370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522514370?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078600,"startTime":"0","endTime":"0","summary":"HOUSTON, March 27, 2025  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US10Y.BOND","IRD","NVDD","FBLG","IMRX","USAU","XOMA","US30Y.BOND","ET","NVDS.UK","US2Y.BOND","US7Y.BOND","DXYN","DM","ADVM","NVDY","SNVD.UK","SMXT","NGNE","CCL","NVDL","GORV","US6M.BOND","JVA","BPTH","US3Y.BOND","PURE","FBRX","US5Y.BOND","3NVD.UK","BOLD","AFG","NVDU","2NVD.UK","MPU","US12M.BOND","NVD3.UK","NVIW.SI","OLMA","NVDS","IMNM","PRPH","NVDA","ATXI","NVD2.UK","ZBIO","CKPT","SGMA","NVDX"],"gpt_icon":1},{"id":"2519806034","title":"Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2519806034","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519806034?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:35","pubTimestamp":1741955700,"startTime":"0","endTime":"0","summary":"NEW YORK, March 14, 2025  -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing.The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company’s resource section.Select companies are accepting 1x1 management meeting requests through March 18th.Virtual Investor Conferences  is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance thei","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-science-virtual-investor-forum-123500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PSQ","FBLG","LADX","AVCNF","USAW.SI","QID","COCP","TELIF","BK4179","TNXP","TQQQ","CGTX","TSYW.SI","HMTXF","PDSB","BK4007","NVIW.SI","SQQQ","MNQmain",".IXIC","QLD","NQmain","USJW.SI","FET","NGENF","IZOZF"],"gpt_icon":1},{"id":"2517788990","title":"Uncovering Opportunities: 3 Penny Stocks With Market Caps Under $80M","url":"https://stock-news.laohu8.com/highlight/detail?id=2517788990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517788990?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:05","pubTimestamp":1741172702,"startTime":"0","endTime":"0","summary":"As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly cautious about their next moves. In such a climate, penny stocks—often representing smaller or newer companies—can offer unique opportunities for those willing to explore beyond the blue-chip names. Despite being an outdated term, penny stocks remain relevant as they can combine value and growth potential, especially when backed by strong financials.Overview: FibroBiologics, Inc. is a cell therapy and regenerative medicine company with a market cap of $40.17 million.Operations: FibroBiologics, Inc. currently does not report any revenue segments.FibroBiologics, Inc., with a market cap of US$40.17","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uncovering-opportunities-3-penny-stocks-110502616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4209","BK4179","TTI","BK4021","PVL","FBLG","POCI","BK4213","BK4082","SB","PHX","BABB","BK4563","MLSS"],"gpt_icon":0},{"id":"2517060735","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2517060735","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517060735?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:17","pubTimestamp":1741112220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 13:17 ET (18:17 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2516403679","title":"FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516403679","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516403679?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:30","pubTimestamp":1741095000,"startTime":"0","endTime":"0","summary":"This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.HOUSTON, March 04, 2025  -- FibroBiologics, Inc.   , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts to improve mitochondrial performance in cells.This communication contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts to modulate mitochondrial function, to unlock new treatment options driven by mitochondrial dysfunction, to alter how chronic disease is treated, and to unlock new therapeutic strategies for the treatmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrobiologics-files-patent-novel-approach-133000437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FBLG","LENZ"],"gpt_icon":0},{"id":"2514333789","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514333789?lang=en_us&edition=fundamental","pubTime":"2025-02-28 01:50","pubTimestamp":1740678600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 12:50 ET (17:50 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1730347200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2025-04-17","current":-3.685286,"percent":0.71831,"low":-68.573467,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"high":-1.984604,"avg":-11.043959,"sd":12.222734,"marketCap":41131477},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477}],"updateTime":1745259599998}}}